| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | +30% | $277,876,336 | +$109,228,632 | 7,652,255 | +65% | FMR LLC | 31 Dec 2025 |
| SR ONE CAPITAL MANAGEMENT, LLC | 9.4% | $111,851,442 | 5,037,854 | SR One Capital Management, LLC | 09 Oct 2025 | |||
| InnoCare Pharma Inc. | 9.4% | $111,026,500 | 5,000,000 | InnoCare Pharma Inc. | 07 Oct 2025 | |||
| Enavate Sciences GP, LLC | 7.3% | $87,013,952 | 3,919,159 | Enavate Sciences GP, LLC | 09 Oct 2025 | |||
| MOULDER LEON O JR | 5.2% | +7.2% | $101,943,527 | +$7,704,625 | 2,806,792 | +8.2% | Leon O. Moulder, Jr. | 07 Jan 2026 |
| Longitude Capital Partners IV, LLC | 4.9% | $58,425,578 | 2,631,522 | Patrick G. Enright | 09 Oct 2025 | |||
| Novo Holdings A/S | 4.7% | -12% | $44,400,000 | -$4,772,267 | 2,000,000 | -9.7% | Novo Holdings A/S | 30 Sep 2025 |
As of 31 Dec 2025, 117 institutional investors reported holding 41,561,364 shares of Zenas BioPharma, Inc. - COMMON STOCK (ZBIO). This represents 78% of the company’s total 53,512,273 outstanding shares.
The largest institutional shareholders of Zenas BioPharma, Inc. - COMMON STOCK (ZBIO) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 7,704,255 | +60% | 0.01% | $279,741,500 |
| SR One Capital Management, LP | 9.4% | 5,037,854 | +2.6% | 26% | $182,924,479 |
| ENAVATE SCIENCES GP, LLC | 7.3% | 3,919,159 | +4.2% | 28% | $142,304,663 |
| NEA Management Company, LLC | 6.6% | 3,523,219 | +29% | 6.5% | $127,928,082 |
| FEDERATED HERMES, INC. | 5.1% | 2,715,578 | +46% | 0.16% | $98,602,637 |
| Fairmount Funds Management LLC | 4.1% | 2,209,025 | +17% | 6.1% | $80,209,698 |
| NVP ASSOCIATES, LLC | 3.4% | 1,838,482 | 0% | 26% | $66,755,281 |
| BlackRock, Inc. | 3.3% | 1,767,518 | +44% | 0% | $64,178,579 |
| VANGUARD GROUP INC | 2.7% | 1,453,065 | +25% | 0% | $52,760,791 |
| NOVO HOLDINGS A/S | 2.7% | 1,450,000 | -28% | 4.1% | $52,649,500 |
| Polar Capital Holdings Plc | 2% | 1,057,609 | 0.18% | $38,401,783 | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.6% | 855,334 | -0.26% | 0.01% | $31,057,177 |
| Vivo Capital, LLC | 1.6% | 853,495 | -28% | 2% | $30,990,403 |
| EcoR1 Capital, LLC | 1.5% | 789,500 | 1.3% | $28,666,745 | |
| ArrowMark Colorado Holdings LLC | 1.4% | 751,161 | -8.9% | 0.6% | $27,274,656 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1.1% | 591,991 | -24% | 8.3% | $21,495,193 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 588,393 | +25% | 0% | $21,370,527 |
| Rock Springs Capital Management LP | 0.94% | 502,077 | -14% | 0.94% | $18,230,416 |
| STATE STREET CORP | 0.82% | 438,294 | +16% | 0% | $15,914,455 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.69% | 369,248 | -1.3% | 0% | $13,408,000 |
| Point72 Asset Management, L.P. | 0.69% | 368,400 | 0.01% | $9,213,684 | |
| NEXTBio Capital Management LP | 0.6% | 321,983 | 0% | 6.9% | $11,691,203 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.4% | 213,193 | +20% | 0% | $7,741,038 |
| Balyasny Asset Management L.P. | 0.36% | 193,153 | 0.01% | $7,013,385 | |
| Invesco Ltd. | 0.35% | 187,968 | +29% | 0% | $6,825,118 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 41,561,364 | $1,504,857,228 | +$255,199,514 | $36.31 | 117 |
| 2025 Q3 | 34,774,383 | $771,813,059 | +$23,276,708 | $22.20 | 78 |
| 2025 Q2 | 34,055,191 | $329,977,952 | +$15,611,752 | $9.69 | 72 |
| 2025 Q1 | 32,489,801 | $256,715,238 | +$5,759,402 | $7.90 | 67 |
| 2024 Q4 | 31,699,756 | $259,632,936 | +$20,083,837 | $8.19 | 65 |
| 2024 Q3 | 24,771,152 | $418,526,187 | +$418,475,122 | $16.92 | 44 |